Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus guidelines for the management of plaque psoriasis.
Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr; National Psoriasis Foundation Medical Board. Hsu S, et al. Among authors: crowley j. Arch Dermatol. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410. Arch Dermatol. 2012. PMID: 22250239
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.
Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. Strober B, et al. Among authors: crowley jj. J Am Acad Dermatol. 2009 Jul;61(1 Suppl 1):S1-S46. doi: 10.1016/j.jaad.2009.03.017. J Am Acad Dermatol. 2009. PMID: 19527820
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Strober BE, et al. Among authors: crowley jj. Br J Dermatol. 2011 Sep;165(3):661-8. doi: 10.1111/j.1365-2133.2011.10419.x. Epub 2011 Jul 28. Br J Dermatol. 2011. PMID: 21574984 Clinical Trial.
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1.
Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. Strober BE, et al. Among authors: crowley jj. Dermatol Ther (Heidelb). 2012 Dec;2(1):1. doi: 10.1007/s13555-012-0001-y. Epub 2012 Mar 17. Dermatol Ther (Heidelb). 2012. PMID: 23205324 Free PMC article.
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.
Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. Strober BE, et al. Among authors: crowley jj. Dermatol Ther (Heidelb). 2012 Dec;2(1):2. doi: 10.1007/s13555-012-0002-x. Epub 2012 Mar 30. Dermatol Ther (Heidelb). 2012. PMID: 23205325 Free PMC article.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Papp KA, et al. Br J Dermatol. 2015 Oct;173(4):949-61. doi: 10.1111/bjd.14018. Br J Dermatol. 2015. PMID: 26149717 Clinical Trial.
1,603 results